Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 2, 2006, Pages 302-306

  Elzein, Elfatih ^a   Kalla, Rao ^a   Li, Xiaofen ^a   Perry, Thao ^a   Parkhill, Eric ^a   Palle, Venkata ^a   Varkhedkar, Vaibahv ^a   Gimbel, Art ^a   Zeng, Dewan ^a   Lustig, David ^a   Leung, Kwan ^a   Zablocki, Jeff ^a  

^a CV THERAPEUTICS INC   (United States)

Author keywords

Adenosine; Antagonists; Asthma

Indexed keywords

8 [1 [(3 PHENYL 1,2,4 OXADIAZOL 5 YL)METHYL] 1H PYRAZOL 4 YL] 1,3 DIPROPYL 1H PURINE 2,6(3H,7H) DIONE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

BINDING SITES; DRUG EVALUATION, PRECLINICAL; MOLECULAR STRUCTURE; PYRAZOLES; RECEPTOR, ADENOSINE A2B; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

ANIMALIA;

EID: 27944489028     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.10.002     Document Type: Article

References (17)

1. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, K.N. Klotz, and L. Linden Pharmacol. Rev. 53 2001 527
2. B.B. Fredholm, M.P. Abbraccio, G. Burnstock, J.W. Daly, T.K. Harden, K.A. Jacobson, P. Leff, and M. Williams Pharmacol. Rev. 46 1994 143
3. A.S. Kirschenbaum, B. Hettinger, Y.J. Day, A.M. Gilfilian, D.D. Metcalfe, Y.C. Kim, J. Linden, and K.A. Jacobson J. Allergy Clin. Immunol. 107 2001 S281
4. C.J. Meade, L. Worrall, D. Hayes, and U. Protin Biochem. Pharmacol. 64 2002 317
5. I. Feoktistov, and I. Biaggioni J. Clin. Invest. 96 1995 1979
6. P.J. Hughes, S.T. Holgate, and M.K. Church Biochem. Pharmacol. 33 1984 3847
7. P.T. Peachell, L.M. Lichtenstein, and R.P. Scheimer J. Pharmacol. Exp. Ther. 256 1991 717
8. I. Feoktistov, E.M. Garland, A.E. Goldstein, D. Zeng, and L. Belardinelli Biochem. Pharmacol. 62 2001 1163
9. R. Volpini, S. Costanzi, S. Vittori, G. Cristalli, and K.-N. Koltz Curr. Top. Med. Chem. 3 2003 427
10. P.G. Baraldi, M.A. Tabrizi, D. Preti, A. Bovero, R. Romagnoli, F. Fruttarolo, N.A. Zaid, A.R. Moorman, A. Varani, S. Gessi, S. Merighi, and P.A. Borea J. Med. Chem. 47 2004 1434
11. Kalla, R.; Perry, T.; Elzein, E.; Li, X.; Varkhedkar, V.; Palle, V.; Ibrahim, P.; Xiao, D.; Zablocki, J. U.S. Patent 6825349, 2004.
12. Kalla, R.; Perry, T.; Elzein, E.; Palle, V.; Li, X.; Varkhedkar, V.; Maa, T.; Nguyen, M.; Wu, Y.; Maydanik, V.; Lustig, D.; Leung, K.; Zeng, D.; Zablocki, J. Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, Mar 28-Apr 1, 2004; MEDI-253.
13. 2B adenosine receptor antagonists containing an amide bond have less liver S9 metabolic stability. MRS-1754 (1), which contains an amide bond, is also metabolically unstable. In addition, we have successfully replaced the amide bond with oxazoles, isoxazoles, and oxadiazoles, and that resulted in compounds with enhanced metabolic stability.
14. J. Zablocki, R. Kalla, T. Perry, V. Palle, V. Varkhedkar, D. Xiao, A. Piscopio, T. Maa, A. Gimbel, J. Hao, N. Chu, K. Leung, and D. Zeng Bioorg. Med. Chem. Lett. 15 2005 609
15. E. Elzein, P. Ibrahim, D. Koltun, K. Rehder, K. Shenk, T. Marquart, B. Jiang, X. Li, R. Natero, Y. Li, M. Nguyen, S. Kerwar, N. Chu, D. Soohoo, J. Hao, V. Maydanik, D. Lustig, D. Zeng, K. Leung, and J. Zablocki Bioorg. Med. Chem. Lett. 14 2004 6017
16. G.A. Patani, and E. LaVoie J. Chem. Rev. 96 1996 3147 and references therein
17. J.W. Daly, W. Padgett, M.T. Shamim, P. Butts-Lamb, and J. Waters J. Med. Chem. 28 1985 487